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Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type
9 Inhibitors Across US Private and Public Payers
Abstract
A comprehensive review of prior authorization (PA) requirements for a new class of expensive
cholesterol-lowering drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has
found unusually complex and burdensome demands across public and private insurance plans in the
United States. These findings raise concerns that current policies may create undue barriers to care even
in medically appropriate patients, particularly since requirements were just as stringent for patients with a
genetic condition that creates more clear-cut eligibility for PCSK9 inhibitor treatment.
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KEYFINDINGS
A comprehensive review of prior authorization (PA) requirements for a new class of expensive cholesterol-lowering
drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has found unusually complex and
burdensome demands across public and private insurance plans in the United States. These findings raise concerns
that current policies may create undue barriers to care even in medically appropriate patients, particularly since
requirements were just as stringent for patients with a genetic condition that creates more clear-cut eligibility for
PCSK9 inhibitor treatment.
THE QUESTION
Are PA requirements for PCSK9 inhibitors serving an appropriate
gatekeeping function or creating excessive barriers to treatment?
Alirocumab (Praluent®) and evolocumab (Repatha®) were approved
by the FDA in 2015 and are thus far the only PCSK9 inhibitors on
the market. These novel biologic medications are an innovative
option for patients with familial hypercholesterolemia or clinical
atherosclerotic cardiovascular disease who require further lowering of
LDL cholesterol. Recently completed long-term outcomes trials for
both PCSK9 inhibitors have shown significant relative risk reductions in
cardiovascular events. In addition, the alirocumab trial reported a lower
risk of death overall, with its protective effects being more pronounced
in high-risk patients.
Initial estimates placed the number of patients eligible for PCSK9
inhibitors at 9-11 million, with annualized spending projections
(depending on uptake assumptions) ranging from $21.4 -$113 billion

after accounting for direct medical cost offsets. The fear of a “budget
busting” effect should these agents see widespread adoption spurred
payers to implement utilization management policies to attenuate the
potential economic impact. Early anecdotal reports indicate that the
PA process for PCSK9 inhibitors has been particularly challenging
for providers, and claims-based studies have reported high rates of
rejections of PCSK9 inhibitor prescriptions, with less than half ultimately
receiving approval after appeals. Given that target patient populations
are at high risk for heart attack or stroke, delays in care related to
administrative hurdles could have serious implications.
Using a unique data source, the authors undertook the first detailed
analysis of administrative and clinical PA requirements for PCSK9
inhibitors under commercial insurance, health insurance exchanges
(HIX), Medicare, and Medicaid, and compared the relative PA burden
for PCSK9 inhibitors to that of two other cardiometabolic drugs,
namely ezetimibe (Zetia®) and liraglutide (Victoza®), that share key
characteristics.
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THE FINDINGS
In 2016, between 82% and 97% of individuals were enrolled in plans
implementing PA for PCSK9 inhibitors (depending on insurance
segment), and one-third to two-thirds of these enrollees faced
PAs restricting prescribing of PCSK9 inhibitors to a specialist
(e.g., cardiologist). For patients with familial hypercholesterolemia,
diagnostic confirmation via genetic testing or meeting minimum
clinical scores/criteria was frequently required. PA requirements
were more extensive for PCSK9 inhibitors than the other
cardiometabolic drugs; forms for PCSK9 inhibitors contained 3 to
11 times the number of PA criteria or fields (Figure 1) and more
frequently required the submission of medical records as supporting
documentation (Figure 2).
Despite minimal explicit step therapy requirements, most patients
(outside of Medicare) were required to try multiple lipid-lowering
drugs before receiving PA approval for PCSK9 inhibitors (i.e.,
implicit step therapy). In addition, there was little consistency
regarding which combinations of lipid-lowering medications or
dosages payers deemed necessary to fulfill these requirements.
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FIGURE 1.
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THE IMPLICATIONS
These findings offer a rare snapshot of PA burden, which
is typically difficult to obtain due to the diverse insurance
market in the US and the fact that PA requirements are not
necessarily publicly available. The analysis identified five
frequent and notable features of PA requirements for PCSK9
inhibitors: 1) more submission requirements for medical record
documentation along with PA form, compared to other drugs
prescribed by the same types of clinicians; 2) requests for
documentation that may be difficult for providers to obtain,
particularly if patients have changed physicians over time (e.g.,
off-treatment cholesterol levels); 3) restriction to specialty
prescribers, despite the fact that high cholesterol is often treated
in primary care; 4) requirements for genetic testing, which is
not standard clinical practice in the US and often not covered
by insurance even when required for PA; and 5) step therapy
requirements that are not in keeping with clinical guidelines.
Collectively, these hurdles may introduce substantial additional
out-of-pocket costs for patients (e.g., lab tests, specialist visit
copays), which could increase the risk of health disparities
among rural and low-income patients and increase the risk
that clinically appropriate patients will not receive treatment. In
addition, the complexity and variation of requirements across
plans also increase the risk of confusion and oversights during
PA completion, which may partly explain previous reports of high
rejection rates for PCSK9 inhibitor prescriptions.

FIGURE 2.

PERCENTAGE OF PATIENTS IN A PLAN THAT REQUIRES A
PROVIDER TO SUBMIT MEDICAL RECORDS AS PART OF
THE PA PROCESS
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Given the cost of PCSK9 inhibitors and the number of patients potentially eligible
for treatment, payer concerns over the budget impact of these therapies are justified.
However, these findings raise the question of whether current PA policies are limiting
access to these drugs for even high-risk patients and highlight the relevance of recent
efforts to streamline and standardize PA requirements to reduce provider burden while
ensuring clinically appropriate use. It remains to be seen how payers will respond to
accumulating evidence on PCSK9 inhibitors from long-term cardiovascular outcomes
trials, but striking the right balance between access and affordability will be critical to
ensuring PCSK9 inhibitors provide maximum value to high-risk patients.

THE STUDY
The researchers conducted an analysis of 2016 formulary coverage and PA data from a
large, proprietary database (Decision Resource Group’s Fingertip Formulary) containing
information on policies from 3,872 plans across the four major insurance segments
(commercial, health insurance exchange, Medicare, Medicaid). These data were linked
with enrollment information obtained from Decision Resource Group’s Managed
Markets Surveyor-Rx Suite, a second proprietary database containing membership
information for insurers in the US. The linked data captured the formulary coverage,
tier status, step therapy, and PA requirements for PCSK9 inhibitors for over 95% of
Americans (275.3 million lives) who had insurance coverage in 2016.
Key measures included administrative PA criteria (prescriber specialty, number of
criteria in PA policy or number of fields on PA form, requirements for medical record
submission, reauthorization requirements) and clinical/diagnostic PA criteria (approved
conditions, required labs or other tests, required concomitant therapy, step therapy
requirements, continuation criteria) for each of the two FDA-approved PCSK9 inhibitors
approved at that time (alirocumab [Praluent®] and evolocumab [Repatha®]). Select
measures were obtained for two comparator cardiometabolic drugs (ezetimibe [Zetia®]
and liraglutide [Victoza®]).

FUNDING SOURCE

This study was supported by Regeneron and Sanofi. The funding sources had no role in
the design and conduct of the study; management, analysis, or interpretation of the data;
preparation or approval of the manuscript; or the decision to submit the manuscript for
publication.

ResearchBRIEF
ABOUT LDI
Since 1967, the Leonard Davis Institute of
Health Economics (LDI) has been the leading
university institute dedicated to data-driven,
policy-focused research that improves our
nation’s health and health care. Originally
founded to bridge the gap between scholars
in business (Wharton) and medicine at the
University of Pennsylvania, LDI now connects
all of Penn’s schools and the Children’s
Hospital of Philadelphia through its more than
250 Senior Fellows.
LDI Research Briefs are produced by
LDI’s policy team. For more information
please contact Janet Weiner at
weinerja@pennmedicine.upenn.edu.

COLONIAL PENN CENTER
3641 LOCUST WALK
PHILADELPHIA, PA 19104-6218
LDI.UPENN.EDU
P: 215-898-5611
F: 215-898-0229
@PENNLDI

Doshi JA, Puckett JT, Parmacek
MS, Rader DJ. Prior Authorization
Requirements for Proprotein Convertase
Subtilisin/Kexin Type 9 Inhibitors Across
US Private and Public Payers. Circulation:
Cardiovascular Quality and Outcomes,
2018 Jan;11(1):e003939. doi: 10.1161/
CIRCOUTCOMES.117.003939.

LEAD AUTHOR
DR. JALPA DOSHI
Jalpa Doshi, PhD is Professor of Medicine at Penn’s Perelman School of Medicine. Her work applies health economics, outcomes research,
and policy methods to address issues related to pharmaceutical access, costs, outcomes, and value. In recent years, her research program
has particularly focused on specialty drugs for serious, rare, and/or chronic diseases. Dr. Doshi is Director of Value-Based Insurance Design
Initiatives at the Center for Health Incentives and Behavioral Economics and Director of the Economic Evaluations Unit of the Center for
Evidence-Based Practice at the University of Pennsylvania Health System.

